Radioimmunotherapy Consolidation using (131)I-Tositumomab for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

Despite initial responses to chemoimmunotherapy, relapse and minimal residual disease (MRD) remain major issues in treatment of CLL/SLL patients. We administered 131I-tositumomab to patients in CR or PR after induction chemotherapy. Toxicities and rate of PR to CR conversion and MRD elimination were...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Leuk Lymphoma
Asıl Yazarlar: Shadman, Mazyar, Gopal, Ajay K., Kammerer, Britt, Becker, Pamela S., Maloney, David G., Pender, Barbara, Shustov, Andrei R., Press, Oliver W., Pagel, John M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4798884/
https://ncbi.nlm.nih.gov/pubmed/26133724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1067701
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller